The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

A report published Tuesday shows hundreds and thousands of percent markups on HIV, hypertension and cancer drugs for Medicare ...

The "Big 3" PBMs also separately generated an estimated $1.4 billion of income from spread pricing, FTC finds.